Amycretin
A single molecule investigated for combined GLP-1 and amylin-receptor activity.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Clinical Trials
Investigational; not FDA-approved for the uses discussed.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A single molecule investigated for combined GLP-1 and amylin-receptor activity.
Investigational; not FDA-approved for the uses discussed.
Formulation-specific program milestones differ, and early weight outcomes are not mature cardiovascular or mortality evidence.
Why It's Being Studied
- Obesity research
- GLP-1 and amylin signalling
Mechanism of Action
It activates complementary satiety and metabolic receptor pathways; it is not a fixed mixture of two separate medicines.
It activates complementary satiety and metabolic receptor pathways; it is not a fixed mixture of two separate medicines. Formulation-specific program milestones differ, and early weight outcomes are not mature cardiovascular or mortality evidence.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Obesity research
- GLP-1 and amylin signalling
- Oral clinical research
- Subcutaneous clinical research
Evidence Summary
Early randomized human studies demonstrate weight reduction, with development advancing toward phase 3 during 2026.
Higher tiers carry more weight. Filled tiers have evidence for Amycretin; tap to read it.
- Early randomized human studies demonstrate weight reduction, with development advancing toward phase 3 during 2026.
1 cited sources.
- Regulatory document1
Human clinical evidence
- Early randomized human studies demonstrate weight reduction, with development advancing toward phase 3 during 2026.
Reported Adverse Events in Research
- Gastrointestinal adverse effects and limited long-term safety evidence are key considerations.
Limitations of Current Evidence
- Formulation-specific program milestones differ, and early weight outcomes are not mature cardiovascular or mortality evidence.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Amycretin | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Clinical Trials | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Oral clinical research, Subcutaneous clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
Amycretin — regulatory document